ArticleAnnals of pediatric endocrinology & metabolism2024
An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database).
Article in Annals of pediatric endocrinology & metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 10 citations in OpenAlex.
- A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency.The Journal of clinical endocrinology and metabolism · 2025Trial
- Weekly somatrogon vs daily somatropin: a propensity score-matched analysis of growth outcomes from clinical data vs KIGS.Journal of the Endocrine Society · 2026Article
- Growth Hormone Treatment Response and Machine Learning-Based Prediction in Idiopathic GHD and ISS: Analysis of the Korean LG Growth Study.Clinical endocrinology · 2026Observational
- Beyond anatomy - A commentary on "Pituitary magnetic resonance imaging abnormalities and 1-year growth response in children with idiopathic growth hormone deficiency".Annals of pediatric endocrinology & metabolism · 2026Article
- Pituitary magnetic resonance imaging abnormalities and 1-year growth response in children with idiopathic growth hormone deficiency.Annals of pediatric endocrinology & metabolism · 2026Article
- Association between recombinant human growth hormone therapy and refractive status in Korean children with idiopathic short stature: a cross-sectional study.Scientific reports · 2026Article
- Linear growth and metabolic outcomes of growth hormone treatment in childhood-onset craniopharyngioma: the OUTSPREAD study.Pediatric research · 2026Article
- Final adult height in Korean children with idiopathic growth hormone deficiency after growth hormone treatment.Scientific reports · 2026Article
- Long-Term experience with growth hormone therapy in pediatric growth disorders: an analysis of the LG growth study data.Endocrine · 2026Observational
- Real-Life Growth Hormone Treatment Patterns in Children from China: A Report from Two Databases.Advances in therapy · 2025Observational
- Impact of growth hormone therapy on bone and body composition in prepubertal children with idiopathic short stature.Journal of pediatric endocrinology & metabolism : JPEM · 2025Article
- Commentary on "Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations".Annals of pediatric endocrinology & metabolism · 2025Article
- Metabolic changes after growth hormone treatment in children with growth hormone deficiency and small for gestational age: LG observational study.Frontiers in endocrinology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Kabi International Growth Study (KIGS) was first established in 1987 and is the largest pharmaco-epidemiological study of recombinant human growth hormone (rhGH). KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. KIGS data have been used to answer multiple research questions related to growth, growth prediction, and growth hormone treatment, leading to the publication of 129 peer-reviewed manuscripts and 24 biannual reports, outcomes from 10 expert meetings, and 3 books. The KIGS has shown that rhGH is safe and increases both the short-term height gain and adult height in patients with GH deficiency (GHD) and multiple other non-GHD conditions associated with short stature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.